  SCCM Technology Excellence Award
The Society for Critical Care Medicine (SCCM) has chosen Masimo
Corporation as the recipient of this year’s SCCM Technology Excellence Award.
This award, which recognizes outstanding strides in technology which benefit
critical care medicine, will be formally given to Joe E. Kiani, Founder and
President of Masimo Corporation, at the SCCM Conference to be held in Orlando,
Florida from February 11 through February 15.
This is the first year such an award is being given to someone
in the industry. The SCCM Awards had previously been given only to clinicians
and non-industry researchers. According to the SCCM, “Masimo’s design convinced
intensivists that pulse oximetry could work on the toughest patients and be
useful during motion and low perfusion, thus raising the bar in the standards
critical care medicine can now apply to future technology.”
“It is important that true technological innovators be
recognized and rewarded for their efforts,” commented Max H. Weil, MD, PhD,
FCCM, Distinguished University Professor and founder of the SCCM. “Prior to
Masimo’s contributions, the false alarms and unreliability of pulse oximeters
were assumed to be inherent and insurmountable limitations of the measurement.
Masimo did not accept this and made an intuitive leap to create what is now the
new standard of performance for pulse oximeters. Having dedicated my career to
advancing the care of critically ill patients, I am happy to see that better
care will result and the standards are being raised as a result of Masimo’s
technological breakthrough. Masimo has truly earned this award.”
 Frost & Sullivan Market Engineering Competitive Strategy Award
Masimo Corporation announced that it is the recipient of one of
Frost & Sullivan’s highest honors for Market Engineering: the 2000
Competitive Strategy Award. This award, based on independent research and
analysis of companies in the health care industry, recognizes Masimo for its
positive contribution to the blood gas monitoring equipment market.
According to Frost & Sullivan analyst, Minal Vasanawada,
“Masimo has made a significant impact on the industry with its successful
marketing of its proprietary Signal Extraction pulse oximetry technology, Masimo
SET®. False alarms and erroneous readings due to patient and environmental
factors have for long plagued pulse oximetry technology. By addressing this
pressing need to have more accurate data from pulse oximeters in varied clinical
settings including motion and low perfusion, Masimo has displayed a clear
understanding of the primary competitive factors in this industry. Frost &
Sullivan recognizes this outstanding achievement and awards Masimo with its
Competitive Strategy Award.”
“Masimo is honored to be recognized by Frost & Sullivan for
the advancement and contribution Masimo has made in the field of pulse
oximetry,” said Joe E. Kiani, President and CEO of Masimo Corporation. “Our goal
was to solve what other companies thought was unsolvable - to make pulse
oximetry accurate during motion and low perfusion. We then set out to educate
the industry and health care professionals with independent clinical studies by
leading clinicians around the world and true side-by-side demonstrations. Today,
over 25 clinical studies by independent researchers have proven Masimo Signal
Extraction Technology to be the only pulse oximetry technology accurate under
the most challenging conditions of motion and low perfusion and when it’s needed
the most. We wish to thank the dedicated clinicians who, without any personal
monetary reward, have spent their valuable time and resources to study Masimo
SET’s performance compared to conventional pulse oximetry and Masimo SET’s
effect on improving patient care as well as reducing cost of care.”
Mr. Kiani continued, “By proving the breakthrough accuracy and
reliability of Masimo SET technology clearly and honestly, we have been able to
attract over 30 leading patient monitoring companies, who make up over 50% of
the world’s pulse oximeter suppliers - to adopt Masimo SET as their standard
pulse oximetry technology. These companies have spent significant resources to
upgrade their products to Masimo SET for the benefit of their customers; they
should also be honored. Receiving honors such as this Frost & Sullivan Award
and the appreciation from clinicians and patients who have been helped by our
technology, renews our commitment to continue to advance signal processing and
sensor technology for the benefit of patients and to be driven by a sense of
fascination and accomplishment.”
Recently Masimo announced Radical, a product that is
accelerating the standardization of Masimo SET pulse oximetry throughout
hospitals. The Radical Signal Extraction pulse oximeter allows clinicians to get
access to Masimo SET. It is three pulse oximeters in one: a standalone device
for bedside monitoring, a detachable handheld pulse oximeter for ultra-portable
monitoring and a monitor interface, called SatShare, which allows Radical to
upgrade multi-parameter patient monitors to Masimo SET technology. Radical can
provide continuous and reliable arterial oxygen saturation monitoring anywhere
throughout the continuum of care. With help from some of our partners,
particularly Allegiance and Datex-Ohmeda, who have vast distribution resources
and flexible acquisition programs, Masimo is making it easy for clinicians to
get access to Radical to standardize their hospitals to Masimo SET pulse
oximetry.
 AEA 2000 High Tech Award Winner- Outstanding Medical Device Company
Masimo Corporation announced that it is the recipient of the
2000 American Electronics Association (AEA) award for Outstanding Medical Device
Company. This award, presented as part of the Seventh Annual
High-Tech
Awards event of the Orange County Council, is presented to the company
demonstrating excellence in technological innovation and leadership in the
medical device industry.
The High-Tech Awards honor a wide range of high-technology
categories including Outstanding Medical Device Company, Outstanding Public
Company, Outstanding Software Company, Outstanding Internet Company, Outstanding
Executive (public and private company), Mentor/Angel, and Innovative
Product/Technology.
According to Phil Beaudoin, executive director, Orange County
Council, AEA, “These companies and executives serve as outstanding examples of
the innovative technology that continues to be developed and enhanced at the
local level. They have set the precedent for technology growth in Orange County
for the new century.”
“Masimo is honored to be recognized by the American Electronics
Association,” said Joe E. Kiani, President and CEO of Masimo Corporation.
“Masimo is a classic Orange County start-up. Eleven years ago, we started in a
garage and our goal was, and still is, to make a contribution by developing
better technology for patient care. In our pursuit of this goal, we have been
fortunate to develop a technology that today, is not only saving lives and
improving patient care, but is also reducing the cost of care. Over 25 clinical
studies by independent researchers have proven Masimo Signal Extraction
Technology to be the only pulse oximetry technology accurate under the most
challenging conditions of motion and low perfusion and when it’s needed
most.”
Mr. Kiani continued, “This award belongs to everyone on the
Masimo Team, our employees, advisors, investors, clinical researchers, and the
business community in Orange County, who believed in us, encouraged and
supported us.”
 Medical Design Excellence Award for Radical™ Signal Extraction Pulse Oximeter
Masimo Corporation, the innovator of Signal Extraction Pulse
Oximetry, has been selected as winner in the 2001 Medical Design Excellence
Awards (MDEA) competition for Masimo’s recently released Signal Extraction
Technology™ Pulse Oximeter, Radical™. The MDEA is the only awards program
devoted exclusively to recognizing contributions and advancements in the design
of medical products. MDEA-winning products excel in the areas of product
innovation, design and engineering excellence, end-user benefit, and
cost-effectiveness in manufacturing and healthcare delivery.
An impartial,
multi-disciplinary panel of third-party jurors reviews all products submitted.
These jurors have expertise in biomedical engineering, human factors, industrial
design, medicine, nursing, diagnostics, and medical packaging. Winners are
selected in ten medical product categories. Radical was selected as a winner in
the division of Critical Care and Emergency Products.
Radical Signal Extraction Pulse Oximeter is three pulse
oximeters in one: a standalone device for bedside monitoring, a detachable
handheld pulse oximeter for portable monitoring or spot check, and with its rich
interface options, including SatShare™, provides an upgrade path for the
conventional pulse oximetry technologies found in hospital patient monitors to
Masimo SET performance.
Radical incorporates a new version of Masimo SET software, V3™,
which not only delivers the breakthrough motion and low perfusion performance of
Masimo SET, but debuts FastSat™, which allows pulse oximeters to accurately
track rapid saturation changes with unprecedented fidelity. Radical also debuts
Signal IQ™, a unique visual indication that identifies the arterial pulse and
quality of the acquired signal even under conditions of motion and low
perfusion.
“Radical, is the most advanced pulse oximeter in the world, yet
it is simple to use,” said Joe E. Kiani, President and Chief Executive Officer
of Masimo Corporation. “Clinicians from around the world contributed to the
design of Radical by challenging our engineers to take the Masimo SET engine and
design a pulse oximeter body around it that would make it available to all of
their patients in all of the environments they were currently using conventional
pulse oximetry or couldn’t due to the limitations of conventional pulse
oximeters. They also wanted one intuitive user interface for all of their
applications, whether they were doing spot-check hand-held pulse oximetry
measurement or continuous bedside monitoring in the OR, ICU or Ward.”
Mr. Kiani continued, “Due to the requirements and feedback by
our clinical advisory group, and the ingenuity and hard work of our engineers,
clinicians around the world can now benefit from Masimo SET’s unprecedented
sensitivity and specificity for all their patients in all of the environments
they choose; all with one intuitive user interface. We thank MDEA for this
recognition, as well as, the many clinician advisors, our engineering team and
the industrial design team of I.N. for creating Radical.”
AEA Innovative Product/Technology Award
Masimo Corporation, the innovator of Signal Extraction Pulse
Oximetry, was honored by the American Electronics Association's (AEA) Orange County Council at
its Eighth Annual High Tech Awards ceremony last night. The AEA recognized the
Masimo Radical Signal Extraction pulse oximeter, as the Innovative
Product/Technology in the medical area.
The Radical has quickly become recognized as the most advanced
and versatile pulse oximeter ever conceived. In addition to providing the
unsurpassed accuracy and reliability of Masimo SET pulse oximetry, Radical
possesses several other features that set it apart. Its removable, battery
operated module allows it to be quickly converted from a standalone bedside
monitor to a handheld device, which can be used for transport or spot checks.
Masimo's SatShare interface cable may also be used with the Radical pulse
oximeter to upgrade existing monitors to Masimo SET performance. Many hospitals
have found the SatShare interface to be most economical means of upgrading their
existing monitors.
The versatility and multi-functionality of the Radical pulse
oximeter make it the best solution for a hospital looking to replace all of its
pulse oximetry technology with the newly recognized motion and low perfusion
tolerance standards set by Masimo. A facility can replace its standalone and
handheld devices with Radical pulse oximeters, and upgrade its integrated
monitoring systems with SatShare. Then, all patients in the facility benefit
from the improved performance of Masimo SET and clinicians do not need to decide
which patients get the new technology and which can risk the old. And, with
sensor standardization achieved, the hospital can keep a long lasting Masimo
single patient adhesive sensor on the patient throughout their stay. Many
hospitals, including Massachusetts General, are standardizing their entire
facility on Masimo SET.
"We are honored that the AEA has recognized Masimo with this
award," said Joe E. Kiani, President and Chief Executive Officer of Masimo
Corporation. "Radical is the result of input from clinicians around the world
who were looking for a pulse oximetry solution that met all of their needs. Our
talented and dedicated team went beyond the call of duty in designing and
building a product that meets these needs. I'm proud to say, based on the
clinical and market response to Radical so far, that we achieved our goal and
have delivered a product to the market that can allow clinicians to improve the
level of care while saving money in the process. We thank the AEA, and I thank
my team for their valiant effort."
The Huntington’s Disease Society of America Distinguished Leadership Award
Irvine, California November 19, 2001 - Joe E. Kiani, President
& CEO of Masimo Corporation, was presented with the Huntington's Disease
Society of America's (HDSA) Distinguished Leadership Award at the First Annual
HDSA Orange County Celebration of Hope Dinner last week. The HDSA Distinguished
Leadership Award is a nationally recognized award associated with the
Celebration of Hope Dinners, which benefit HDSA Centers of Excellence in cities
around the country. The award is presented to individuals who have had a
positive impact in their communities, and for the significant contributions they
have made in their chosen fields.
Mr. Kiani was recognized for his
accomplishments in founding Masimo Corporation, the innovator of Masimo SET -
Signal Extraction Technology - which is used in the healthcare field as the
premier noninvasive patient monitoring technology. Since its worldwide market
release in 1998, Masimo SET has emerged as the preeminent pulse oximetry
(measuring a patient's arterial blood oxygen saturation) technology,
particularly under the most challenging conditions of patient motion and low
perfusion (low blood flow). Other recipients of the Distinguished Leadership
Award included:
Ralph Cygan, M.D. - CEO of and Clinical Professor at UC
Irvine Medical Center
John Hagestad - Chairman, Orangewood Children's
Foundation; Executive
Committee Member, Sares Regis Group
Arthur
B. Birtcher - Co-Chair, Birtcher Real Estate Group
"Huntington's Disease
is a degenerative, fatal genetic disorder that can absolutely devastate families
who are affected by it," said Joe E. Kiani, President and Chief Executive
Officer of Masimo Corporation. "I am honored to receive the Distinguished
Leadership Award, but, more importantly, I am hopeful that events such as the
Celebration of Hope dinners, will serve to bring awareness and support in the
fight to end Huntington's Disease."
Masimo Corporation, founded in 1989,
is a privately held medical technology company that develops, licenses and
markets advanced medical signal processing technologies and products for the
noninvasive monitoring of vital signs. Masimo Signal Extraction Technology
represents a fundamental departure from conventional pulse oximetry
technologies. Over 50 independent, published studies have demonstrated that
Masimo Signal Extraction Technology substantially overcomes the limitations of
conventional pulse oximeters in accurately measuring arterial blood oxygen
saturation levels and pulse rates in the presence of patient movement and low
perfusion. To date, Masimo has licensed its Signal Extraction pulse oximetry OEM
MS Boards and proprietary LNOP single patient adhesive and reusable sensors to
over 35 international patient monitoring system providers which make up over 60%
of the world's pulse oximeter shipments. AmeriNet, the leading group purchasing
organization and HealthTrust Columbia, the largest hospital system in America
are offering their member hospitals the ability to gain access to Masimo SET
technology at group purchasing discounted prices. Masimo is headquartered in
Irvine, California. Additional information about Masimo and its products can be
found on the company's web site www.masimo.com.
Huntington's Disease
(HD), named for Dr. George Huntington who first discovered the disease in 1872,
is a fatal and degenerative brain disorder for which there is, at present, no
effective treatment or cure. HD, which is passed down to 50% of the children of
a parent having the disorder, slowly diminishes the affected individual's
ability to walk, talk and reason. The Huntington's Disease Society of America is
dedicated to providing support and education to the families affected by this
life-altering illness, and to ultimately finding a cure. HDSA Centers of
Excellence provide clinical care, counseling, referrals and education for
individuals with HD and their families. HDSA Centers of Excellence are supported
through Celebration of Hope events and through the generosity of the community
and HD family and friends.
Frost & Sullivan Product Quaility Leadership Award
Frost & Sullivan bestows the Market Engineering Award for
Quality Control Leadership upon the company that has demonstrated superior
quality control÷over their existing competitors÷in product manufacturing.
Quality control is an essential element of satisfying customers, increasing
repeat buying behavior, and assuring long-term market survival.
Research Methods:
To choose the award recipient, the analyst team tracks all products and
research and development projects within the industry. This is accomplished
through interviews with all market participants, end-users, distributors,
and extensive secondary and technology research.
|
 |
Measurement Criteria:
In addition to the methodology
described above, there is specific criteria used to determine final competitor
rankings in this industry. The award recipient has excelled based on one or more
of the following criteria:
- Lowest defect percentage per batch of units
produced by suppliers in current base year
- Product ability to fulfill
customer needs, in terms of functionality and user friendliness
- Number of
breakdowns or services required per year
- Degree of connectivity
- Level
of product support end-users receive from their vendors or
suppliers
Product Quality Leadership Award: Masimo
Corporation:
The recipient of the 2002 Frost & Sullivan Product
Quality Leadership Award for the U.S. fetal and neonatal market is Masimo
Corporation.
Masimo is a leading supplier of advanced medical signal
processing technologies and products for the noninvasive monitoring of patient
vital signs. Masimo Corporation is a privately held medical technology company,
and is responsible for developing innovative motion and low perfusion tolerant
pulse oximetry. The Masimo Signal Extraction Technology (Masimo SET) is a
breakthrough technology to access, process and register arterial oxygen
saturation and pulse rate. Masimo SET enhances the accuracy of SpO2 monitoring,
particularly in complex patient conditions such as motion and low peripheral
perfusion. Masimo SET utilizes five algorithms (as opposed to the traditional
two) to ensure continuous, accurate SpO2 measurement, even under the most
challenging conditions.
Over 50 clinical studies have proved that the
Masimo SET considerably reduces costs, improves patient outcomes, and reduces
medical errors in the presence of patient movement and low perfusion. Masimo has
licensed its Signal Extraction pulse oximetry technology to over 35
international patient monitoring systems providers, accountable for 60 percent
of the world's pulse oximeter shipments. Moreover, over 35 patient monitoring
equipment manufacturers market Masimo SET pulse oximetry. Some of the most
notorious companies competing in the fetal and neonatal monitoring equipment
market that offer Masimo's SET pulse oximetry are: Datascope, GE Medical
Systems, Invivo Research Inc., Ivy Biomedical Systems, Inc., Medical Data
Electronics (MDE), a subsidiary of Viasys Healthcare, Respironics, and Welch
Allyn.
For its commitment to the highest standards of excellence in its
product offerings, Frost & Sullivan is proud to present the 2002 Product
Quality Leadership Award to Masimo Corporation.
March of Dimes Excellence in Leadership Award
The Orange County Division of the March of Dimes held its 7th
Annual Excellence in Leadershipo Gala on Thursday, October
18, 2001, at 6:00 p.m. at the Hyatt Newporter in Newport Beach. The non-profit
that saves babies' lives recognized four Orange County individuals for their
contribution to the March of Dimes mission, and for their significant
achievements and outstanding leadership in their fields. The black tie dinner
was attended by over 352 participants and raised $140,000 in support of the
March of Dimes.
The Jonas Salk Excellence in Medicine Award was awarded
to M. Douglas Cunningham, M.D., Vice President, Special Projects, Pediatrix
Medical Group, Inc. An accomplished physician, teacher and researcher, Dr.
Cunningham was honored for his contributions to the field of neonatal-perinatal
medicine.
The Excellence in Leadership Awards were presented to: Joe E.
Kiani, president and CEO, Masimo Corporation, for his outstanding contributions
in the biomedical technology field; Tim Smith, CEO and president, Fountain
Valley Regional Hospital & Medical Center, for his ongoing effort and
achievements in the medical field; and Alex Stenzler, vice president, Advanced
Technologies, Sensor Medics Corporation, for his extraordinary endeavors in the
biomedical technology field.
Heading the Honorary Committee were Bill
Ross, honorary event chair and chief operating officer for Viasys Healthcare,
along with Deborah Harrington, chair, Orange County Division Board of Directors
and manager, Investment Management Services for Harrington Capital. Serving
along with Ross and Harrington were Jeffrey C. Barbakow, Tenet HealthSystem;
Valerie Begnoche, Masimo Corporation; Steve Bredehoft, Sensor Medics
Corporation; Thomas J. Burnham, The Allergan Foundation; Michele Finney, Los
Alamitos Medical Center; Lynn Hayes, Pediatrix Medical Group; Jannie Herchuk,
Deloitte & Touche; Chris Kilpatrick, Arter & Hadden; Roger J. Medel,
M.D., Pediatrix Medical Group, Kathleen O'Brien, Fountain Valley Regional
Hospital & Medical Center; Meredith Rattay, Grossman Burn Center; LeAnn
Spaide, Glendale Adventist Medical Center; and Mike Stephens of Hoag
Hospital.
The annual gala helped increase awareness of the March of Dimes
and its accomplishments in serving the mothers and babies of Orange County.
Funds raised helped provide continuing support for research, community programs,
public education and advocacy in the fight against birth defects, prematurity,
and infant mortality.
The black tie evening began with a cocktail
reception at 6:00 p.m., followed by dinner and the awards presentation at 7:15
p.m. Tickets were $250.00. For additional event information, contact Hanna Koh
at (949) 263-1100 or email Hkoh@modimes.org.
The March of Dimes is a
national voluntary health agency whose mission is to improve the health of
babies by preventing birth defects, prematurity, and infant mortality. Founded
in 1938, the March of Dimes funds programs of research, community service,
education, and advocacy to save babies. The Southern California Chapter serves a
population of more than 20 million people and has divisions in Los Angeles, San
Diego, Orange County and the Inland Empire. More information is available on the
March of Dimes web sites at www.modimes.org and www.nacersano.org.
THE
ORANGE COUNTY DIVISION OF THE MARCH OF DIMES 7TH ANNUAL EXCELLENCE IN LEADERSHIP
GALA 2001 HONOREES
JONAS SALK EXCELLENCE IN MEDICINE AWARD
M.
Douglas Cunningham, M.D., joined Pediatrix as Chief Medical Officer in 1996 and
has served on the Board of Directors for Pediatrix Medical Group since that
time. Currently he serves as vice president of Special Projects at Pediatrix
Medical Group. Dr. Cunningham has dedicated 32 years to research and clinical
interests in pediatrics. He has co-authored a book that has been translated in
four languages, 16 chapters have been utilized in medical textbooks, 34 articles
have been published in medical journals and in 57 scientific
presentations.
EXCELLENCE IN LEADERSHIP AWARD
Joe E. Kiani is the
co-founder of Masimo Corporation. He has served as its president, CEO and
Chairman of the Board of Directors since Masimo's inception in 1989. Kiani is an
inventor on more than 30 patents related to signal processing, sensors and
patient monitoring. Masimo licenses its technology to more than half of the
world's patient monitoring suppliers, making Masimo SET technology available to
customers in a wide array of product configurations.
Tim Smith has served
in the healthcare management field for 20 years and currently serves as
president and CEO at Fountain Valley Regional Hospital and Regional Center.
Smith is a Diplomate of the American College of Healthcare Executives and
participates in the University of California, Los Angeles Mentoring Program. He
is the recipient of the 2000 Ethics in America Award from Chapman
University.
Alex Stenzler currently serves as vice president of Advanced
Technologies for Sensor Medics Corporation and the Critical Care Division of
Viasys Healthcare Corporation where he has worked for 10 years. Sensor Medics
designs, manufactures, markets and services advanced diagnostic and therapeutic
products for the respiratory care market. Stenzler, always concerned about the
respiratory health of babies and adults alike, has done extensive research on
the passive measurement system for respiratory mechanics.
Frost & Sullivan New Standard of Care in Patient Monitoring Award
San Jose, Calif. - June 16, 2003 - Frost & Sullivan today
presented the first the 2003 New Standard of Care in Patient Monitoring Award to
Masimo Corporation, a developer of advanced medical signal processing
technologies instrumental in state-of-the-art noninvasive monitoring of patient
vital signs, at the AMMI Conference in Long Beach, California.
Aroop Zutshi, Frost & Sullivan senior partner,
presented the award to Joe E. Kiani, Chairman and CEO of Masimo Corporation, in
recognition of its commitment to patient care, its successful pioneering and
introduction of
next-generation pulse oximetry technology, and its
demonstrated improvement of patient monitoring. |
|
In 1996,1997, and 1998, Masimo introduced in Europe, Japan and
the US respectively, its pioneering Signal Extraction Technology (Masimo SET®)
solution, the first motion-tolerant and low-perfusion monitoring device, into
the pulse oximetry and patient monitoring markets. Initially blocked from
selling its product to the US hospitals through group purchasing organizations
(GPOs), Masimo went directly to leading medical professionals and had its
product assessed and compared against the leading pulse oximeters of the day.
These independent studies highly favored the Masimo SET® solution,
raising the awareness of improvements in the medical community and creating
strong demand for this motion-tolerant technology among healthcare workers.
Prior to Masimo SET pulse oximetry, pulse oximeters were fraught with false
alarms. In fact, approximately 90% of the pulse oximeter alarms were false with
conventional pulse oximetry. The dramatic reduction in the number of false
alarms, and the improvement in detection of true alarms, was felt to
significantly improve the caregiver's productivity as well as provide reliable
continuous patient pulse oximetry data.
Masimo's low-perfusion technology
also enables doctors and healthcare workers to measure oxygenation levels in
patients which were previously unable to be measured and regulated. Clinical
studies had shown that over 10% of the time pulse oximeters failed to provide
any measurement during surgery in the OR. Masimo SET changed all of that. As a
result, new standards of care are now being offered to patients from infants to
geriatrics.
"The rapid adoption of Masimo SET® technology, by both
hospitals and major patient monitoring equipment manufacturers demonstrates the
value that the market has placed on this significant technological advancement,"
says Katherine Shariq, Frost & Sullivan industry analyst.
The Frost
& Sullivan New Standard of Care in Patient Monitoring Award is given to a
company that has successfully developed or introduced a new or advanced version
of a patient monitoring component or device, which could potentially
revolutionize or reinvigorate the market. Multiple advantages over existing
monitoring components clearly establish that the technology used in the field
has evolved into a next-generation device. Masimo is the first company to
receive such an honor over the past 15 years.
About Masimo Corporation
Founded in 1989, Masimo Corporation, the innovator of motion and
low perfusion tolerant pulse oximetry, is a privately held medical technology
company that develops, licenses and markets advanced medical signal processing
technologies and products for the noninvasive monitoring of patient vital signs.
Masimo Corporation is headquartered in Irvine, California.
About Frost & Sullivan
Founded in 1961, Frost & Sullivan, a global leader in growth
consulting, presents Market Engineering Awards to companies that demonstrate
excellence in their industry, commending the diligence and innovative business
strategies required to advance in the global marketplace. Frost & Sullivan
rigorously analyzes specific criteria to determine Market Engineering Award
recipients in a vast variety of market industries and landscapes. For further
information, visit www.frost.com
Frost & Sullivan Patient Monitoring Technology of The Year Award SAN DIEGO, Nov 6, 2003 - At last night's 2003 Global Excellence
in Healthcare & Life Sciences Awards Banquet, Frost & Sullivan named
Masimo Corporation as the recipient of the 2003 Patient Monitoring Technology of
the Year Award.
| Masimo Corporation's innovative Signal Extraction
Technology (Masimo SET®) modernized the pulse oximetry and patient monitoring
markets with its ease of use and breakthrough performance. |
|
| Its ability to noninvasively measure oxygen
saturation levels in high-risk and difficult patients, such as people with very
low levels of perfusion and those actively in motion, has created widespread
demand by physicians. |
"Masimo's engineering design and skilled development of highly
specific algorithms have made its technology highly sought after," states
Katherine Shariq, industry analyst with Frost & Sullivan. "Due to the
company's innovations, the pulse oximetry market has been reenergized and the
use of pulse oximetry solutions for continuous measurements among high-risk
patients has expanded."
This award recognizes Masimo's contribution to medicine and
patient care through its innovation, engineering expertise, and diligence in
getting its Masimo SET technology accepted and used in the patient monitoring
market. Masimo currently maintains licensing agreements with more than 35
international patient monitoring equipment providers and operates a growing
stand-alone pulse oximeter business.
With Masimo SET acknowledged as a new technology standard most
hospitals and caregivers are making the shift to "next-generation" pulse
oximetry solutions to monitor their patients. Masimo deserves this award for its
commitment to patient care, reliability, and the ease of use of its products.
Joe E. Kiani, Chairman & CEO of Masimo stated, "On behalf of
the Masimo team, both those inside and outside the company, I would like to
thank Frost and Sullivan for bestowing upon us this award. This award not only
encourages us to do more, but hopefully it encourages other people to dedicate
themselves to the advancement of patient care."
Every year, Frost & Sullivan honors the company that
introduces a technology with the ability to influence and impact R&D focus
and competitive posture in several market segments. The technology also shows
potential to become an industry standard or achieve a high degree of market
acceptance. Held in San Diego, Calif., the Frost & Sullivan banquet
honored world-class companies for outstanding performance and achievements in
the healthcare industry. An annual event, the banquet recognizes the quality and
merit of these distinguished companies.
About Masimo
Masimo, founded in 1989, is the innovator and leader of motion
and low perfusion tolerant pulse oximetry. Masimo develops, licenses and markets
advanced medical signal processing technologies and products for the noninvasive
monitoring of vital signs. Masimo Signal Extraction Technology represents a
fundamental departure from conventional pulse oximetry technologies. Over 70
independent and objective published studies have demonstrated that Masimo SET is
the safest and most effective pulse oximetry technology in the world. To date,
Masimo has licensed its Signal Extraction Pulse Oximetry technology to over 35
international patient monitoring system providers, which make up over 70 percent
of the world's pulse oximeter shipments. Masimo is headquartered in Irvine,
Calif. Additional information about Masimo and its products can be found on www.masimo.com.
About Frost & Sullivan
Founded in 1961, Frost & Sullivan is recognized as a global
leader in growth consulting. Frost & Sullivan Awards are presented to
companies that demonstrate excellence in their industry, commending the
diligence, commitment, and innovative business strategies required to advance in
the global marketplace. Frost & Sullivan rigorously analyzes specific
criteria to determine award recipients in a vast variety of market industries
and landscapes. For further information, visit www.frost.com.
Platinum "ABBY" Award --Adaptive Business Leaders Innovations in Healthcare Award
Orange, CA (June 20, 2003) - Joe Kiani, CEO of Masimo
Corporation (in Irvine), Jay Short, Ph.D., CEO of Diversa Corporation (in San
Diego) and Adam Singer, M.D., CEO of IPC-The Hospitalist Company (in North
Hollywood), respectively took home the Platinum, Gold and Silver "ABBY" Awards
at the Adaptive Business Leaders (ABL) Organization's Fifth Annual Innovations
in HealthcareSM Awards and Event, held Wednesday, June 18, at the Hyatt Regency,
Irvine.
The three innovators were selected to receive the gold statuette
from among a group of nine Innovations in HealthcareSM finalists for their
outstanding advancements to the field of healthcare in medical technology, bio
technology and information technology-enhanced healthcare services. According to
Mimi Grant, President of ABL, the 60-plus judges, primarily ABL Members and
other healthcare industry CEO's and Division heads attending the Event, found
their greatest challenge of the day was selecting just three companies to win
the ABBY among the nine finalists, each of whom presented a compelling case as
to why and how their product or service significantly advanced the quality of
patient life or enabled the business of healthcare to be conducted more cost
effectively.o
Joe Kiani, CEO of Masimo Corporation, took home the Platinum
"ABBY.o Masimo has developed proprietary signal processing and sensor
technologies for cost-effective, noninvasive patient monitoring, improving
patient outcomes and reducing the cost of care through its Masimo SET Pulse
Oximetry technology. Joe has also brought leadership to the medical technology
industry by breaking through the often bureaucratic hurdles established by some
large healthcare systems and Group Purchasing Organizations.
Jay Short, Ph.D., CEO of Diversa Corporation received the Gold
Innovations in HealthcareSM Award. Diversa is a leader in the discovery,
evolution, and production of commercially valuable molecules with pharmaceutical
applications, such as optimized monoclonal antibodies and orally active drugs.
The company also developed a cutting edge technology that allows ultra
high-throughput, resulting in faster new drug discovery, enabling the
fast-tracking of the next cancer or autoimmune disease treatment development.
Adam Singer, M.D. and CEO of IPC - The Hospitalist Company was
awarded the Silver "ABBY." In 1991, IPC pioneered hospitalist care: full-time,
acute primary care specialists who focus exclusively on patients receiving
inpatient care. IPC-LINK® is the company's proprietary clinical
repository of best practices (and much more) that each of IPC's 400 physicians
can easily access on their wireless hand-held computers, thus increasing
economic efficiency while enhancing quality of care.
The other finalists included:
David Adamson, M.D., is
Chairman and CEO of Advanced Reproductive Care, Inc, which is the only national
organization of physician specialists in fertility care, who also have developed
innovative payment plans.
Eleanor Levin, M.D., is the Clinical Lead of Kaiser Permanente's
Comprehensive Coronary Artery Disease Program, which has dramatically reduced
the number of Kaiser patients suffering and dieing from coronary artery disease
Bob Watson is President and CEO of Concuity, Inc., which
provides an enterprise-wide information system that helps providers create and
negotiate better contracts with payers and collect what's owed them.
John O'Shaughnessy is President of Government Management
Services, Inc., which created and operates FACIS®, the Fraud and
Abuse Control Information System, for verifying the credentials of, and reports
sanctions against, physicians and other clinicians.
Ed Fotsch, M.D. is CEO of Medem, Inc., which, backed by the AMA,
developed this physician-patient communications network to facilitate online
access to information and care for more than 90,000 physicians and their
patients.
Richard Brumley, M.D. is the Physician in Charge of Kaiser
Permanente's TriCentral Palliative Care Program, which cares for those with
serious, advanced, life-limiting illnesses and is focused on their quality of
life.
About the ABL Organization
From its inception, 20 years ago,
the purpose of the Adaptive Business Leaders Organization (ABL; originally named
SO/CAL/TEN) has been the sharing of best practices and innovative approaches
that propel business growth. Today the Organization facilitates nine monthly
Round Tables (from San Diego to San Francisco) and holds special forums
throughout the year -- like Innovations in HealthcareSM -- that enable its
healthcare and technology Members to learn from each other. Further, for ABL's
healthcare Members there is a particular focus on how to cost-effectively apply
innovative approaches to delivering high quality healthcare.
MD&DI 100 Notable People in Medical Device Industry awarded to Joe Kiani
MD&DI Names Joe E. Kiani as one of its 100 notable people in
the medical device industry.
 Joe E. Kiani, the company's co-founder and CEO has been recognized
for his contributions to the medical device industry by the editors of Medical
Device & Diagnostic Industry(MD&DI) , a Canon Communications LLC
publication. Mr. Kiani was selected as the one of the magazine's 100 notable
people and featured in the June 2004 issue of MD&DI. "We selected our 100
notable people on the basis of their contributions to the medical device and
healthcare industries," said Canon Communications Editorial Director John
Bethune. "The individuals chosen reflect the outstanding achievements of the
people behind today's medical technology." The medical device industry is well
known for its technology, a central aspect that MD&DI covers in each and
every issue. Less often noted are the many outstanding people without whom that
technology would not exist. The June issue marks the first time MD&DI pays
special tribute to 100 of these individuals.
Joe Kiani
Chairman and CEO
Masimo Corp.
A named inventor on more than 30 patents for signal processing,
sensors, and patient monitoring...helped start-up company grow to have 300
employees, a global technology-license, and product-distribution agreements.
The Forum for Corporate Directors -- Director of the Year for Corporate Growth
Laguna Niguel, CA (February 25, 2004) - Joe Kiani, CEO, Masimo
Corporation, took home the Forum for Corporate Directors' (FCD) Director of the
Year Award. Mr. Kiani built Masimo Corporation from a tiny start-up to a 450+
employee, multi-national company that dramatically changed pulse oximetry with
their innovation of Masimo SET, a proprietary method of picking up
difficult-to-read signals. His leadership also built bridges to Group Purchasing
Organizations, paving the way for other small companies to gain access to
previously unavailable market segments.
|
About Forum for Corporate Directors
The Forum for
Corporate Director's mission is to promote the highest standards of corporate
ethics and best governance practices, create forums for director peer
interactions, and enhance director effectiveness through high-quality and timely
education and development programs.
Forum for Corporate Directors membership includes 200 of Orange
County's most prominent business and community leaders, corporations and
professional services organizations. Forum members are committed to creating
value for their organizations, promoting the highest standards of corporate
ethics and sharing their experiences with their fellow members and directors.
|
About Masimo
Masimo, founded in 1989, is the innovator and leader of motion
and low perfusion tolerant pulse oximetry. Masimo develops, licenses and markets
advanced medical signal processing technologies and products for the noninvasive
monitoring of vital signs. Masimo Signal Extraction Technology represents a
fundamental departure from conventional pulse oximetry technologies. Over 70
independent and objective published studies have demonstrated that Masimo SET is
the safest and most effective pulse oximetry technology in the world. To date,
Masimo has licensed its Signal Extraction Pulse Oximetry technology to over 35
international patient monitoring system providers, which make up over 70 percent
of the world's pulse oximeter shipments. Masimo is headquartered in Irvine,
Calif. Additional information about Masimo and its products can be found on www.masimo.com.
Deloitte & Touche Technology Fast 50, Orange County  WHAT: Deloitte & Touche LLP, one of the nation's
leading professional services firms, is pleased to announce an alphabetical
listing of its 2004 Orange County Technology Fast 50 winners. The Fast 50 ranks
the 50 fastest-growing technology companies in Orange County over five years
(1999-2003). A special category called "Rising Stars" recognizes the five
fastest-growing technology companies based
on revenue growth over three years
(2001-2003).
HOW: Technology Fast 50 winners are selected based on the
percentage of growth in fiscal year revenues from 1999 to 2003. To be
considered, entrants must be based in Orange County and must be a technology
company defined as owning proprietary technology that contributes to a
significant portion of the company's operating revenues (using other companies'
technology in a unique way does not qualify); and/or devoting a significant
proportion of revenues to research and development of technology.
WHEN:
Announcement of the Orange County Technology Fast 50
winners ranked by growth percentage and the Rising Star winners is scheduled for
October 4, 2004.
WHERE:
Visit www.fast50.com for more information on the
Technology Fast 50 program.
WHO:
Acacia Research Corporation, Accenx Technologies, Inc.,
Aircept.com LLC(a), Allergan, Inc., Artemis International Solutions Corporation,
Autobytel Inc., BIOLASE Technology, Inc., Broadcom Corporation, Callipso
Corporation, Cardiac Science, Inc., Ceradyne, Inc., ChromaVision Medical
Systems, Inc., Cortex Pharmaceuticals, Inc., DPAC Technologies Corp., Dynatem,
Inc, eEye Digital Security, Electropure, Inc., Emulex Corporation, Endocare,
Inc., Envision Financial Systems, Inc., Exult Inc., Foundstone, Inc.(a),
HireRight, Inc., I/OMagic Corporation, ICU Medical, Inc., I-Flow Corporation,
Infokall, Inc.(a), Interpore Cross International, Inc., Island Pacific, Inc.,
KOR Electronics, Lantronix, Inc., Lifemasters Supported Self Care, Inc.,
Masimo Corporation, Meade Instruments Corp., MenuLink Computer
Solutions, Inc., Micro Therapeutics, Inc., MSC.Software Corporation, netGuru,
Inc., Oakley, Inc., Paciolan, Inc., QLogic Corporation, Quality Systems, Inc.,
Quest Software, Inc., Raining Data Corporation, Ritz Interactive, Inc., Syagen
Technology, Inc., Sybron Dental Specialties, Inc., TCI Solutions, Inc.,
Telogis(a), The TriZetto Group, Inc., TransDimension, Inc., TTM Technologies,
Inc., U-Nav Microelectronics Corporation(a), Universal Space Network, Inc., US
LABS, Inc.
About Deloitte
Deloitte, one of the nation's leading
professional services firms, provides audit, tax, financial advisory services
and consulting through nearly 30,000 people in more than 80 U.S. cities. Known
as an employer of choice for innovative human resources programs, the firm is
dedicated to helping its clients and its people excel. "Deloitte" refers to the
associated partnerships of Deloitte & Touche USA LLP (Deloitte & Touche
LLP and Deloitte Consulting LLP) and subsidiaries. Deloitte is the US member
firm of Deloitte Touche Tohmatsu. For more information, please visit Deloitte's
web site at www.deloitte.com/us.
Deloitte Touche Tohmatsu is an organization of member firms
devoted to excellence in providing professional services and advice. We are
focused on client service through a global strategy executed locally in nearly
150 countries. With access to the deep intellectual capital of 120,000 people
worldwide, our member firms, including their affiliates, deliver services in
four professional areas: audit, tax, financial advisory services and consulting.
Our member firms serve more than one-half of the world's largest companies, as
well as large national enterprises, public institutions, locally important
clients, and successful, fast-growing global growth companies.
Deloitte Touche Tohmatsu is a Swiss Verein (association), and,
as such, neither Deloitte Touche Tohmatsu nor any of its member firms has any
liability for each other's acts or omissions. Each of the member firms is a
separate and independent legal entity
operating under the names "Deloitte,"
"Deloitte & Touche," "Deloitte Touche Tohmatsu" or other related names. The
services described herein are provided by the member firms and not by the
Deloitte Touche Tohmatsu Verein. For regulatory and other reasons certain member
firms do not provide services in all four professional areas listed above.
Masimo CEO Joe Kiani Receives SDSU 2005 Monty Award
 IRVINE, California
–March 7, 2005 – Masimo®, the inventor of Read-Through Motion & Low
Perfusion Pulse Oximetry, is proud to announce that its CEO and Founder, Joe E.
Kiani, has received the prestigious 2005 Monty award from San Diego State
University. This annual honor recognizes the outstanding achievements and
success of prominent SDSU alumni from each of the school’s academic colleges,
and Mr. Kiani received the College of Engineering 2005 Monty Award. This year’s
award ceremonies were held Saturday, March 5th.
 Mr.
Kiani received both his undergraduate and graduate degrees in electrical
engineering from San Diego State University in the 1980’s, and founded Masimo in
1989 shortly after completing his formal education. He has served as CEO and
chairman since that time, and co-invented Masimo SET® Pulse Oximetry with friend
and engineer, Mohamed Diab, applying system theory and adaptive signal
processing to dramatically improve the monitoring of pulse rate and oxygen
saturation in the blood. This month Masimo announced its second major advance in
patient monitoring with Masimo Rainbow™ SET Pulse CO-Oximetry™, a new technology
that allows caregivers to noninvasively measure carbon monoxide concentration of
the blood, for the first time. The Masimo Rainbow SET platform is designed to
allow for the monitoring of additional parameters like methemoglobin (SpMet™),
as well as arterial oxygen saturation completely noninvasively.
“When we consider candidates, we look not only for success and
innovation, but also for evidence that the university played some role in that
success,” reported Professor David T. Hayhurst, Dean of Engineering at SDSU.
“Joe Kiani did stellar work here in electrical and computer engineering, and
that has clearly been applied brilliantly in the development of Masimo SET Pulse
Oximetry, which has gone on to become an international standard. We are equally
impressed with his perseverance in doing what was necessary to overcome numerous
significant obstacles in turning his scientific breakthrough into a real
product, and then successfully penetrating a market that is very difficult to
enter. We are extremely proud to recognize Joe for all his accomplishments.”
“As an educator I persistently address the questions: ‘Am I
getting through to them? Am I making a difference in their lives? How do I
measure if I am?’” says Professor Fredric Harris, Cubic Signal Processing Chair
of the Department of Electrical and Computer Engineering at SDSU. “One way is by
reviewing the accomplishments of my former students. Joe Kiani is an example of
a former student that every teacher wishes he had by the room-full. Joe is a
creative individual who directed his native intelligence and SDSU-acquired
education to a class of medical instrumentation problems. He recognized them as
an opportunity to apply advanced signal processing techniques. As founder of
Masimo Corp., in the best tradition of entrepreneurship, he guided development
of a novel class of high performance medical instrumentation methods that have
revolutionized patient monitoring systems. The Monty award Joe received at the
33rd Alumni Association Awards Gala is SDSU’s public recognition of the success
of one our distinguished alumni. His award is much deserved and I am proud to
know Joe as a faculty member, as an advisor, and as a friend.”
Masimo, founded in 1989, is the inventor and leader of Signal
Extraction Technology for the non-invasive monitoring of vital signs. Masimo
develops, licenses, and markets advanced medical signal processing technologies and product. Masimo Signal Extraction Technology, or Masimo SET, represents the
standard of care for pulse oximeters. With its introduction in 1996, Masimo SET
overcame data dropouts, false alarms and inaccurate measurements due to patient
motion, low perfusion and other challenging conditions. Over 100 clinical
studies support the conclusion that Masimo SET is the most effective pulse
oximeter in the world.
With the advent of Rainbow Technology, Masimo ushers a new era
for noninvasive monitoring, where patients at risk of respiratory and cardiac
complications, carbon monoxide poisoning and other life threatening diseases can
be safely, noninvasively and accurately monitored with Pulse CO-Oximetry. Masimo
is headquartered in Irvine, California. Additional information about Masimo and
its products can be found at www.masimo.com.
Masimo, Signal Extraction Technology and SET are registered
trademarks of Masimo Corporation. Signal Extraction is a trademark of Masimo
Corporation. Rainbow, Pulse CO-Oximetry, SpCO, and SpMet are trademarks of
Masimo Laboratories.
Contact: Brad Langdale
Masimo Corporation
blangdale@masimo.com (949) 297-7009
|
